Minova Life Science

Minova life sciences - Pharmaceutical company

Trialex-500 Injection

Power that never bows down



Ceftriaxone sodium  250 mg/500mg/1000mg


  • Sepsis
  • Intra-abdominal Infections
  • Abdominal infections
  • Bacterial Septicemia
  • Skin and Skin Structure Infections
  • Urinary Tract Infections
  • Respiratory Tract Infections




  • The sulbactam-Ceftriaxone combination provides the unique properties of a broad-spectrum antibiotic with the added advantage of a wide-spectrum ẞ-lactamase inhibitor.
  • Provides 94.6% higher clinical efficacy against Ceftriaxone resistant strain as compared to Ceftriaxone alone.
  • Shows higher effectivity and bacterial eradication rate in respiratory and urinary tract infections as compared to cefoperazone/sulbactam.
  • Provides higher clinical cured patients in lower RTI as compared to Co-Amoxiclav


                                                                                                           Combined Power that Excels

Explore other products

Scroll to Top